Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Lovestone

Showing results (11-20 of 333) with videos related to

Pageof 34
Sort By:
Age and Ageing|March 5, 2003
Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implicationsClive Holmes, Simon Lovestone
Journal of Clinical Psychopharmacology|July 14, 2009
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezilLatha Velayudhan, Simon Lovestone
Nature Aging|July 15, 2025
The GNPC provides a proteomic resource for biomarker discovery and mechanistic insight in neurodegenerative diseaseSimon Lovestone, Farhad Imam,
Neurology|July 10, 2002
Psychotic genes or forgetful ones?Simon Lovestone, John Hardy
Trends in Neurosciences|January 22, 2002
Alzheimer's disease-do tauists and baptists finally shake hands?Amritpal Mudher, Simon Lovestone
International Psychogeriatrics|August 21, 2004
Is MCI really just early dementia? A systematic review of conversion studiesMaddalena Bruscoli, Simon Lovestone
Biomarkers in Medicine|April 14, 2010
Blood-based biomarkers of Alzheimer's disease: challenging but feasibleMadhav Thambisetty, Simon Lovestone
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Advanced glycation end products, dementia, and diabetesSimon Lovestone, Ulf Smith
Clinical Pharmacology and Therapeutics|November 24, 2019
Will We Have a Drug for Alzheimer's Disease by 2030? The View From PharmaSimon Lovestone, Husseini K Manji
Computational and Structural Biotechnology Journal|November 23, 2016
Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics ApproachAlejo J Nevado-Holgado, Simon Lovestone
Pageof 34

Showing results (11-20 of 333) with videos related to

Sort By:
Pageof 34
Age and Ageing|March 5, 2003
Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implicationsClive Holmes, Simon Lovestone
Journal of Clinical Psychopharmacology|July 14, 2009
Smell identification test as a treatment response marker in patients with Alzheimer disease receiving donepezilLatha Velayudhan, Simon Lovestone
Nature Aging|July 15, 2025
The GNPC provides a proteomic resource for biomarker discovery and mechanistic insight in neurodegenerative diseaseSimon Lovestone, Farhad Imam,
Neurology|July 10, 2002
Psychotic genes or forgetful ones?Simon Lovestone, John Hardy
Trends in Neurosciences|January 22, 2002
Alzheimer's disease-do tauists and baptists finally shake hands?Amritpal Mudher, Simon Lovestone
International Psychogeriatrics|August 21, 2004
Is MCI really just early dementia? A systematic review of conversion studiesMaddalena Bruscoli, Simon Lovestone
Biomarkers in Medicine|April 14, 2010
Blood-based biomarkers of Alzheimer's disease: challenging but feasibleMadhav Thambisetty, Simon Lovestone
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2014
Advanced glycation end products, dementia, and diabetesSimon Lovestone, Ulf Smith
Clinical Pharmacology and Therapeutics|November 24, 2019
Will We Have a Drug for Alzheimer's Disease by 2030? The View From PharmaSimon Lovestone, Husseini K Manji
Computational and Structural Biotechnology Journal|November 23, 2016
Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics ApproachAlejo J Nevado-Holgado, Simon Lovestone
Pageof 34